Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Spicer

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|September 30, 2017
Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High YieldsKristina M Ilieva, Judit Fazekas-Singer, Daniela Y Achkova, et al.
Cells|July 11, 2020
Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical OutcomeHeather J Bax, Jitesh Chauhan, Chara Stavraka, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman, D H Josephs, H Cambrook, et al.
Allergy|February 23, 2020
Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidateHeather J Bax, Atousa Khiabany, Chara Stavraka, et al.
Scientific Reports|July 15, 2016
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skinLouise Saul, Kristina M Ilieva, Heather J Bax, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
The Journal of Clinical Investigation|March 5, 2013
IgG4 subclass antibodies impair antitumor immunity in melanomaPanagiotis Karagiannis, Amy E Gilbert, Debra H Josephs, et al.
Frontiers in Immunology|February 11, 2021
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor AntibodiesZena N Willsmore, Robert J Harris, Silvia Crescioli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
European Journal of Immunology|January 15, 2021
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of actionZena N Willsmore, Ben G T Coumbe, Silvia Crescioli, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|September 30, 2017
Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High YieldsKristina M Ilieva, Judit Fazekas-Singer, Daniela Y Achkova, et al.
Cells|July 11, 2020
Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical OutcomeHeather J Bax, Jitesh Chauhan, Chara Stavraka, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman, D H Josephs, H Cambrook, et al.
Allergy|February 23, 2020
Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidateHeather J Bax, Atousa Khiabany, Chara Stavraka, et al.
Scientific Reports|July 15, 2016
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skinLouise Saul, Kristina M Ilieva, Heather J Bax, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
The Journal of Clinical Investigation|March 5, 2013
IgG4 subclass antibodies impair antitumor immunity in melanomaPanagiotis Karagiannis, Amy E Gilbert, Debra H Josephs, et al.
Frontiers in Immunology|February 11, 2021
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor AntibodiesZena N Willsmore, Robert J Harris, Silvia Crescioli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
European Journal of Immunology|January 15, 2021
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of actionZena N Willsmore, Ben G T Coumbe, Silvia Crescioli, et al.
Pageof 8